Ethical Challenges in Genetic Editing of Haematologic Disorders: Patient Consent and Social Implications

Abstract Genetic editing is a transformative technology in the treatment and management of haematologic disorders. Genome-editing technique has the potential to correct disease-causing mutations at the molecular level. However, these advances are transformative, but this technique is also surrounded by complex ethical challenges. Informed consent remains one of the most pressing ethical concerns. Furthermore, social inequities are important in determining access to these therapies. The treatment costs are also very expensive, which will be only accessible to patients in wealthy regions. The resource-constrained countries are facing challenges that include inadequate infrastructure, lack of regulatory frameworks and limited financial resources. Gene editing in haematologic disorders is advanced but raises key ethical and practical concerns. Germline editing is opposed due to safety risks and potential social inequality. In paediatric cases, it can create a problem in future autonomy. Further challenges include a lack of long-term data, global standards and high costs. Ethical guidelines, public engagement, cost subsidies and long-term research are important. A balanced, patient-centred approach is essential for responsible use of this gene-editing technology.